7 blurbs
One important reason why accelerating clinical trials is a good idea is that we want people to get access to new medicines sooner. But another reason is that there is a robust literature that shows pharma companies do mo…
Back in May, science sleuth Sholto David came across a suspicious image from the major life-sciences supplier Thermo Fisher. It was a Western blot showing the performance of one of their antibodies that is commonly used …
Antimicrobial resistance poses a challenge to normal incentives for invention. It’s driven by the overprescription of antibiotics, and so any new antibiotics we discover we might prefer to keep in reserve, to be used onl…
The great blogger known as owlposting has an awesome new podcast episode with Alex Rubinsteyn and Ben Vincent, two scientists who work on cancer immunotherapy, on ‘How to design a cancer vaccine’. The general idea behind…
Drug development fails 95% of the time, making biotech a brutal investment environment. So how does the industry keep the money flowing? Abhishaike Mahajan, also known as Owl Posting, has a great post on the financial en…
Separately, Niko McCarty and I wrote a round-up of news you might have missed in biotech and medicine . For example, did you know that organ donations have become vastly more efficient because of improvements in preservi…
I’ve also been following the BioNTech announcement that co-founders Ugur Sahin and Özlem Türeci will leave the company by year-end to start a new biotech focused on next-generation mRNA therapeutics (their third startup)…